Board appointment at Aeterna Zentaris
This article was originally published in Scrip
Aeterna Zentaris, a late-stage oncology drug development company specialising in oncology and endocrinology, has elected Michael Meyers to its board of directors. He is a co-founding member, chief executive officer and chief investment officer of Arcoda Capital Management. Before that, Mr Meyers was a partner and portfolio manager at GoldenTree Asset Management.